A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) Recombinant Fusion (F) Nanoparticle Vaccine, With or Without Aluminum Adjuvant, in Healthy Subjects 24 to less than 72 Months of Age

Trial Profile

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) Recombinant Fusion (F) Nanoparticle Vaccine, With or Without Aluminum Adjuvant, in Healthy Subjects 24 to less than 72 Months of Age

Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2016

At a glance

  • Drugs RSV F protein vaccine-Novavax (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novavax
  • Most Recent Events

    • 27 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 22 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 15 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top